Clinical Trial Search

Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years

Primary: Percentage of Participants Who Experienced Event-Free Survival (EFS) Events as Per Independent Review Committee (IRC) Assessment — 52.5; 68.9 percentage of participants

Primary: Part I: Objective Response Rate (ORR) of Single-agent Cediranib in Participants With Advanced Alveolar Soft Part Sarcoma (ASPS) — 0; 0; 0; 1 Participants

Primary: Number of Participants With Engraftment — 23 Participants

Primary: Percentage of Participants With Overall Tumor Response (Response Rate) — 0; 0; 0; 0 Percentage of Participants

Primary: Cumulative Incidence (Estimated Percentage of Participants) Who Developed Toxicities Following Radiation Treatment — 17.7 percentage of participants

Primary: Event-free Survival — 0.3401; 0.4500 Estimated probability

Primary: Lesion-specific Local Control at 6 Months Post-SBRT as Assessed by Percentage of Lesions Locally Controlled — 95 percentage of lesions

Primary: Number of Participants With an Immune Response to Tumor-specific and Non-tumor Specific Peptides During a Period of Immune Reconstitution — 9; 23 Participants

Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants

Primary: Percentage of Evaluable Participants Achieving Progression-Free Survival (PFS) at 3 Months — 81.8 percentage of participants

Primary: Minimal Response Rate in Pediatric Participants With Alveolar Soft Part Sarcoma (ASPS) — 0 Participants

Primary: Number of Participants With Objective Response — 3; 1; 1; 7 Participants

Primary: Number of Participants With Objective Response — 4; 1; 4; 0 Participants

Primary: Complete Remission — 10 participants

Primary: Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib — 280 mg/m²/dose BID

Primary: Number of Participants With Objective Response — 1; 5; 6; 18 Participants

Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events

Primary: Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay — 0; 15 Participants — p=0.043

Primary: Percentage of Participants With Objective Response — 0; 0; 0 percentage of participants

Primary: Number of Participants Who Experienced Serious Adverse Events and Adverse Events — 4; 5 Participants

Primary: Number of Patients With Complete or Partial Response Assessed by RECIST Criteria — 63 percentage of participants

Primary: Response Rate — 0 percentage of participants

Primary: Progression Free Survival (PFS) — NA; NA Months

Primary: Number of Participants Evaluated for Toxicity — 10 Participants

Primary: Objective Response by Response Evaluation Criteria in Solid Tumors Version 1.1 — 0.00; 6.25; 0.00; 0.00 Percent of participants

Primary: Response (Complete Response [CR] and Partial Response [PR]) — 1; 0; 0; 0 participants

Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants

Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001

Primary: Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate — 13; 15; 16; 15 Participants — p=0.35